Changes over time of the daily prednisone dose in patients that responded to anakinra. Changes over time of the daily prednisone dose in patients that.

Slides:

Advertisements

Similar presentations

Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71: doi: /annrheumdis

Advertisements

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

The GR dimer in stromal cells mediates the induction of genes of anti-inflammatory macrophages after DEX treatment in serum transfer-induced arthritis.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.

(A) Lequesne index and quadriceps strength of patients with knee OA

Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.

Sedentary time was higher in non-alcoholic fatty liver disease (NAFLD) than healthy controls with fewer sedentary to active transitions (data reported.

A, B, C, D show outcome results for individual symptoms using GSRS-IBS scoring system and mean symptom severity scores before and after IBS dietetic management.

Percentage of patients achieving EULAR response

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Changes in clinical disease activity over 24 months on a continuous scale in SWEFOT trial participants randomised to triple therapy or anti-TNF with available.

Percentage of smokers using cessation aids, percentage achieving abstinence for 3 months and percentage making a quit attempt (the 1992 survey only asked.

P75NTR and disease severity (A) in persistent oligoarticular (n=29), extended oligoarticular (n=16) and polyarticular (n=13) patients p75NTR mRNA expression.

A, B, C, D show outcome results for individual symptoms using GSRS-IBS scoring system and mean symptom severity scores before and after IBS dietetic management.

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Switching of biological agents (BAs), and achievement of inactive disease and clinical remission (CR). Switching of biological agents (BAs), and achievement.

Bold diamonds are the mean percentage of time with inactive disease during the first 12 months within the subgroup. Bold diamonds are the mean percentage.

EULAR-defined characteristics describing arthralgia at risk for RA

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.

Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.

Step-down efficacy through week 48: categorical CDAI state DMARD-IR (RA-BEAM, RA-BUILD, RA-BEACON) analysis set. Step-down efficacy through week 48: categorical.

Coronal section through the distal interphalangeal joint of the left middle finger shown in figure 2. Coronal section through the distal interphalangeal.

Cumulative changes in mTSS for SB2 and infliximab

Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.

Achilles tendon tear. Achilles tendon tear. (A) Longitudinal and (B) transverse images of the calf: at the middle third of the left Achilles tendon there.

Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia.

Heterogeneity of TCRβ repertoire in autoimmune diseases.

Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

Satisfaction with control of RA

“Tennis Leg”. “Tennis Leg”. Serial Longitudinal images of the calf: (1) There is a well localised hypoechoic collection (C) interposed between the medial.

Top: part of a video EEG recording of patient 1 at age 14 years before adding small doses of lamotrigine to adequate doses of sodium valproate. Top: part.

February 1998 (age 14 years and 8 months).

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to diagnosis of inflammatory bowel disease.

Kaplan-Meier survival plot for primary endpoint of arthritis development. Kaplan-Meier survival plot for primary endpoint of arthritis development. Arthritis-free.

Increased numbers of LDGs in association with disease activity and low complement levels in patients with SLE. Numbers of LDGs were determined by flow.

Calcium pyrophosphate dihydrate crystals extracted from the synovial fluid of a patient with pseudogout viewed under polarised light microscopy. Calcium.

(A) JIA-ACR30/50/70/90 response rates by visit in part 1.

Associations between the ‘% of patients that ever used a bDMARD’ and the ‘composite score clinical criteria’, ‘composite score access to medication’ and.

Frequency distribution of the number of fulfilled classification criteria for RA (ACR 1987) in relation to the proportion of positive anti-CCP antibodies.

Changes over time in DAS 28 (A), SLEDAI (B), glucocorticoid dose (C) and EULAR response (D) in patients with rhupus treated by anti-TNF-α. Box plot (median,

(A) Knees showing marked osteophytes grade III and enthesophytes at the tibial tubercle grade II. (B) Grade III osteophyte around the carpo-metacarpal.

(A–F) Changes of B-cell numbers and B-cell related biomarkers.

Fluoroscopic image of the suprascapular nerve block injection.

Effect sizes (95% CI) of clinical variables per treatment group of studies directly comparing different dosages/routes. Effect sizes (95% CI) of clinical.

Mean disease activity score based on a 28-joint count (DAS28 (ESR)) (A), Clinical Disease Activity Index (CDAI) score (B) and Simplified Disease Activity.

Cox regression analysis of the proportion of patients remaining in remission after stopping azathioprine treatment related to diagnosis of inflammatory.

Kaplan-Meier table analysis of patients with corticobasal degeneration after onset of symptoms; the y axis refers to proportion of patients who are alive.

(A) Sensitivity and specificity values seen in the 827 patients with HSP versus the other forms of childhood vasculitides (c-PAN 150, c-WG 60, c-TA 87).

Serial determinations of both anti-chromatin and anti-dsDNA antibodies in a patient who developed lupus nephropathy during the study period, showing that.

Status of tapering in the first year of follow-up.

Ultrasonographic picture of second metatarsophalangeal joint with synovitis (panel A) and without synovitis (panel B). a, metatarsal head; b, base of.

Dual-energy CT images. Dual-energy CT images. Arrows indicate MSU deposition (MSU deposits colour coded in green). (A) Subject accuracy study with acute.

Diagram of the tendons and ligaments of the fingers showing the potential windows at the interphalangeal joints and the lack of a window at the metacarpophalangeal.

Seven weeks after presentation: scattered posterior pole intra-retinal haemorrhages and cotton wool spots; right eye (A) and left eye (B). Seven weeks.

Statistically significant correlation between the expression of FRP2 or BLT1 in monocytes and different parameters such as ESR (p: 0,0166; r: -0,434),

Patient disposition. *n=1 patient took prohibited concomitant medication due to an adverse event and was discontinued from the study. Patient disposition.

(A) Bar chart presenting the most significantly upregulated and downregulated entities by fold change (FC). (A) Bar chart presenting the most significantly.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Per cent change in lumbar spinal bone mineral density (BMD) at 12 months from baseline in all patients (A), patients stratified by baseline use of glucocorticoid.

Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter.

The right hand of the same patient as in figure 1, photographed from the ulnar side, showing dorsolateral nodes in profile on the index and ring fingers,

(A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy. (A) Percentage of patients achieving remission.

(A) A barium follow-through showing a dilated oesophagus with markedly dilated loops of the small bowel; (B) abdominal computed tomography showing dilated,

Baker’s cyst (photomontage).

Associations between ‘GDP per capita (IntI$)’ and ‘days to work at the minimum wage to cover 30 days of treatment with a bDMARD’ with clinical outcomes.

Associations between ‘GDP per capita’ and ‘days to work at the minimum wage to cover 30 days of treatment with a bDMARD’ with ‘% bDMARD use’. bDMARD, biological.

Presentation transcript:

Changes over time of the daily prednisone dose in patients that responded to anakinra. Changes over time of the daily prednisone dose in patients that responded to anakinra. Mean (SD) of the daily prednisone dose in responders to anakinra before treatment, at 3, 6, 9 months, and at the latest follow-up. Top: SoJIA patients. Bottom: AoSD patients. AoSD, adult-onset Still disease; SoJIA, systemic-onset juvenile idiopathic arthritis. T Lequerré et al. Ann Rheum Dis 2008;67:302-308 ©2008 by BMJ Publishing Group Ltd and European League Against Rheumatism